Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2005

View Archived Issues

MOR-102 study in animal model of psoriasis is inconclusive

Single-shot vaccine protects monkeys against Ebola challenge

Preclinical efficacy of VEGFR2 vaccine in atherosclerosis

A novel mechanism for aspirin as a preventative therapy for atherosclerosis

In vivo evidence of hypolipidemic and antiatherosclerotic effects for TAK-475

Sunesis obtains rights to anticancer compound from BMS

Migenix receives Canadian clearance for phase I/II study of MX-4509

Isotechnika gets go-ahead for phase IIb kidney transplant study of ISA-247

GlaxoSmithKline to acquire Corixa

Serono to develop Genmab's HuMax-TAC

Completion of phase I study of VRX-496 HIV gene therapy

NDA submission for Emezine

Ariad's IND for oral AP-23573 now effective

Life Medical Sciences now known as SyntheMed

Receptor Biologix raises Series A financing to advance Dimercept

Prous Science to host 3rd Annual U.S. Forum

SCH-391 reduces serum testosterone and tumor volume in mouse xenograft model

WAY-181484: Orally available microtubule-binding agent with antitumor activity in vivo

105AD7 vaccine demonstrates activity in osteosarcoma patients

New intravenous formulation of paclitaxel can be rapidly administered

Ranibizumab and verteporfin PDT tested in choroidal neovascularization model

Pharmacokinetics and pharmacodynamics of CHF-3381 studied in healthy volunteers

Oral-lyn insulin spray approved in Ecuador

Novartis files oral iron chelator Exjade in U.S., Europe

Recent patents cover new treatments for metabolic disorders

Update on the safety and immunogenicity of recombinant MVA-BN-based vaccines

New preclinical data on the anticancer efficacy of beta-elemene

New patents cover therapeutic agents for cardiovascular diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...